Antiviral agents encompass a diverse range of pharmaceutical weapons in the ongoing battle against viral infections. Nucleoside analogs, exemplified by acyclovir and tenofovir, disrupt the viral life cycle by interfering with DNA or RNA synthesis, impeding the replication of viruses like herpes and HIV. Protease inhibitors, including ritonavir and lopinavir, play a crucial role in managing retroviruses like HIV by inhibiting the maturation of viral proteins. Neuraminidase inhibitors, such as oseltamivir, prove instrumental in treating influenza by preventing the release of new virus particles. Immunomodulators, like interferons, bolster the host's immune response, aiding in the identification and elimination of virus-infected cells. Entry inhibitors, like maraviroc, block the initial stages of viral infection by preventing the virus from entering host cells. Additionally, the cutting-edge RNA interference (RNAi)-based therapies target viral genes, utilizing the cell's natural defense mechanisms to silence specific viral genetic material, presenting a promising avenue for innovative antiviral interventions.
Title : The role of the humoral innate immune system in evasion of streptococcus pyogenes infections
Francis J. Castellino, University of Notre Dame, United States
Title : Global environmental changes and mosquito-borne diseases in coastal areas
Ranjan Ramasamy, IDFISH Technology, United States
Title : The impact of global antibiotic resistance on the healthcare system, public health, environment and society
Reza Nassiri, Michigan State University, United States
Title : Current topics of adult COVID-19, Influenza, and RS virus patients in Japan
Seki Masafumi, Saitama Medical University International Medical Center, Japan
Title : Novel nanotechnology and its potential applications
Stephen Hsu, Augusta University, United States
Title : 2000 years of pandemics: Past, present and future
Claudia Ferreira, Biophytis Sorbonne, France